Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan

被引：0
|
作者：
Yen-Hsiang Huang
Kuo-Hsuan Hsu
Jeng-Sen Tseng
Tsung-Ying Yang
Kun-Chieh Chen
Kang-Yi Su
Sung-Liang Yu
Jeremy J. W. Chen
Gee-Chen Chang
机构：
[1] Taichung Veterans General Hospital,Division of Chest Medicine, Department of Internal Medicine
[2] National Chung Hsing University,Institute of Biomedical Sciences
[3] National Yang Ming Chiao Tung University,Faculty of Medicine, School of Medicine
[4] Taichung Veterans General Hospital,Division of Critical Care and Respiratory Therapy, Department of Internal Medicine
[5] Chung Shan Medical University Hospital,Division of Pulmonary Medicine, Department of Internal Medicine
[6] Chung Shan Medical University,School of Medicine
[7] National Chi Nan University,Department of Applied Chemistry
[8] National Taiwan University,Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine
[9] National Taiwan University Hospital,Department of Laboratory Medicine
[10] National Taiwan University,Graduate Institute of Clinical Medicine, College of Medicine
[11] National Taiwan University,Center of Genomic and Precision Medicine
[12] National Taiwan University,Institute of Medical Device and Imaging, College of Medicine
[13] National Taiwan University,Graduate Institute of Pathology, College of Medicine
[14] Chung Shan Medical University,School of Medicine and Institute of Medicine
来源：
Targeted Oncology | 2023年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：179 / 180
页数：1
相关论文
共 50 条
  • [1] The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    [J]. TARGETED ONCOLOGY, 2022, 17 (03) : 295 - 306
  • [2] The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
    Yen-Hsiang Huang
    Kuo-Hsuan Hsu
    Jeng-Sen Tseng
    Tsung-Ying Yang
    Kun-Chieh Chen
    Kang-Yi Su
    Sung-Liang Yu
    Jeremy J. W. Chen
    Gee-Chen Chang
    [J]. Targeted Oncology, 2022, 17 : 295 - 306
  • [3] The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan (vol 17, pg 295, 2022)
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    [J]. TARGETED ONCOLOGY, 2023, 18 (01) : 179 - 180
  • [4] Intracranial Efficacy of Afatinib as First-line Treatment in Common/Uncommon EGFR-Mutant Advanced Non-small Cell Lung Cancer Patients
    Liang, Y.
    Kang, L.
    Lin, Y.
    Mai, J.
    Zou, Q.
    Huang, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S345 - S346
  • [5] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [6] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
  • [7] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
    Cheng, Wen-Chien
    Lin, Chi-Chien
    Liao, Wei-Chih
    Lin, Yu-Chao
    Chen, Chia-Hung
    Chen, Hung-Jen
    Tu, Chih-Yen
    Hsia, Te-Chun
    [J]. BMC CANCER, 2024, 24 (01)
  • [8] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
    Wen-Chien Cheng
    Chi-Chien Lin
    Wei-Chih Liao
    Yu-Chao Lin
    Chia-Hung Chen
    Hung-Jen Chen
    Chih-Yen Tu
    Te-Chun Hsia
    [J]. BMC Cancer, 24
  • [9] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
  • [10] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Cam Phuong Pham
    Thi Thai Hoa Nguyen
    Anh Tu Do
    Tuan Khoi Nguyen
    Thi Anh Thu Hoang
    Tuan Anh Le
    Dinh Thy Hao Vuong
    Dac Nhan Tam Nguyen
    Van Khiem Dang
    Thi Oanh Nguyen
    Van Luan Pham
    Minh Hai Nguyen
    Thi Huyen Trang Vo
    Hung Kien Do
    Ha Thanh Vu
    Thi Thuy Hang Nguyen
    Van Thai Pham
    Le Huy Trinh
    Khac Dung Nguyen
    Hoang Gia Nguyen
    Cong Minh Truong
    Tran Minh Chau Pham
    Thi Bich Phuong Nguyen
    [J]. BMC Cancer, 24
12345